RNS Number : 3195Y
Proximagen Group PLC
29 February 2012
PROXIMAGEN GROUP PLC
("Proximagen" or "the Company")
Notification of Preliminary Results
London, UK, 29 February 2011 - Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system and inflammatory diseases, announces that it will issue its preliminary results for the twelve months ended 30 November 2011 on Monday 5 March 2012.
For further information please contact:
Proximagen Group plc
Kenneth Mulvany, Chief Executive Tel: +44 (0)20
Officer 7400 7700
James Hunter, Finance Director
Singer Capital Markets (Nominated
Shaun Dobson/Claes Spang Tel: +44 (0)20
M:Communications (Media enquiries)
Mary-Jane Elliott / Mary Clark Tel: +44 (0)20
/ Hollie Vile 7920 2330
Proximagen Group plc (AIM:PRX) is a European biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and inflammation.
The Company is developing potential new best-in-class therapeutics in its core disease areas including epilepsy, Parkinson's disease, and Alzheimer's disease, as well as in other areas such as inflammation, oncology and neuropathic pain.
Proximagen has a number of existing partnerships with pharmaceutical companies including GlaxoSmithKline, Upsher-Smith and Lundbeck, and is developing a broad pipeline of drug candidate programmes, with four programmes in clinical development and more than ten earlier stage assets being progressed.
Proximagen's strategy is to advance its pipeline with its partners and to acquire innovative drug candidates that complement its pipeline, with the objective of scaling up its risk-mitigated operating model and generating sustainable profits.
For more information, please visit www.proximagen.com.
This information is provided by RNS
The company news service from the London Stock Exchange